JAMA Oncology

Scope & Guideline

Advancing cancer research for a healthier tomorrow.

Introduction

Explore the comprehensive scope of JAMA Oncology through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore JAMA Oncology in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN2374-2437
PublisherAMER MEDICAL ASSOC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2015 to 2024
AbbreviationJAMA ONCOL / JAMA Oncol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885

Aims and Scopes

JAMA Oncology is a leading journal that focuses on advancing the field of oncology through rigorous research, clinical trials, and evidence-based practices. It covers a broad spectrum of topics within oncology, including innovative treatments, health disparities, and the integration of new technologies in cancer care.
  1. Clinical Trials and Treatment Innovations:
    The journal emphasizes the publication of results from clinical trials, particularly those that introduce new therapies or treatment regimens, such as immunotherapy, targeted therapy, and combination therapies.
  2. Health Disparities and Equity in Cancer Care:
    There is a consistent focus on addressing disparities in cancer care, particularly regarding racial, ethnic, and socioeconomic factors that impact treatment access and outcomes.
  3. Molecular and Biomarker Research:
    Research on the molecular mechanisms of cancer and the identification of biomarkers for diagnosis, prognosis, and treatment selection is a core area of interest.
  4. Patient-Centered Care and Quality of Life:
    The journal also prioritizes studies that assess patient-reported outcomes, quality of life, and the psychosocial aspects of cancer treatment.
  5. Integration of Technology in Oncology:
    The integration of new technologies, such as artificial intelligence and telemedicine, into oncology practice is a growing focus, reflecting the changing landscape of healthcare.
JAMA Oncology is adapting to the evolving landscape of cancer research and treatment. Emerging themes reflect significant advancements in the field and a response to contemporary challenges.
  1. Immunotherapy and Combination Treatments:
    The exploration of immunotherapy, particularly in combination with other modalities, is a rapidly growing area, reflecting its critical role in modern oncology.
  2. Health Equity and Access to Care:
    Increasing attention to health equity highlights the need for research that addresses disparities in cancer care access, treatment, and outcomes among diverse populations.
  3. Real-World Evidence and Patient-Centered Research:
    The use of real-world evidence to inform treatment decisions and improve patient outcomes is becoming more prominent, as researchers seek to understand the effectiveness of therapies in routine clinical practice.
  4. Telemedicine and Remote Patient Monitoring:
    The integration of telemedicine and remote monitoring tools in cancer care has surged, particularly in response to the COVID-19 pandemic, highlighting a shift towards more accessible patient care.
  5. Genomic and Precision Medicine Approaches:
    There is an increasing emphasis on personalized medicine, particularly the use of genomic profiling to guide treatment decisions in oncology, reflecting advancements in technology and understanding of cancer biology.

Declining or Waning

While JAMA Oncology continues to thrive in many areas, some themes are showing a decline in publication frequency or relevance. This may indicate shifting priorities in the field or a saturation of specific topics.
  1. Traditional Chemotherapy Studies:
    There has been a noticeable decrease in the publication of traditional chemotherapy studies, as newer treatment modalities like immunotherapy and targeted therapies gain prominence.
  2. Single-Agent Therapy Reports:
    The focus on single-agent therapies is waning, reflecting a broader trend towards combination therapies that enhance efficacy and reduce resistance.
  3. Basic Science Research:
    Basic science studies, particularly those that do not directly translate into clinical applications, are becoming less prevalent, as the journal prioritizes translational and clinical research.
  4. General Population Studies:
    There is a decline in studies solely focusing on cancer incidence or mortality in the general population, as the journal shifts towards more targeted research that addresses specific patient populations and treatment strategies.

Similar Journals

Nature Reviews Clinical Oncology

Advancing the Frontiers of Cancer Care
Publisher: NATURE PORTFOLIOISSN: 1759-4774Frequency: 12 issues/year

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

Cancers

Empowering discovery in oncology and cancer treatment.
Publisher: MDPIISSN: Frequency: 24 issues/year

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

World Journal of Clinical Oncology

Fostering Collaboration in the Fight Against Cancer
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 2218-4333Frequency: 12 issues/year

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

BREAST CANCER RESEARCH AND TREATMENT

Uncovering Breakthroughs in Breast Cancer Treatment
Publisher: SPRINGERISSN: 0167-6806Frequency: 18 issues/year

Breast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.

Cancer Reports

Fostering collaboration in the fight against cancer.
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Reports, published by WILEY, is an esteemed open-access journal dedicated to the field of oncology and cancer research. With a focus on disseminating impactful research findings since its transition to fully open access in 2021, Cancer Reports aims to facilitate knowledge sharing among researchers, clinicians, and healthcare professionals globally. The journal is positioned within the Q3 quartile for both Cancer Research and Oncology categories as of 2023, reflecting its commitment to quality and relevance in a competitive publishing landscape. With an ISSN of N/A and an E-ISSN of 2573-8348, the journal showcases studies across diverse aspects of cancer biology, treatment modalities, and patient care strategies. Located in the United Kingdom at 111 River St, Hoboken 07030-5774, NJ, Cancer Reports strives to contribute to the advancement of cancer research and improve health outcomes for patients worldwide, making it a pivotal platform for scholars and practitioners in the oncology community.

CURRENT PROBLEMS IN CANCER

Bridging Gaps: Illuminating Current Problems in Cancer Management
Publisher: MOSBY-ELSEVIERISSN: 0147-0272Frequency: 6 issues/year

CURRENT PROBLEMS IN CANCER is an esteemed journal published by MOSBY-ELSEVIER, dedicated to advancing the field of oncology and cancer research. With an ISSN of 0147-0272 and an E-ISSN of 1535-6345, it has been a vital resource for over four decades, converging years of expertise from 1976 to 2024. The journal is recognized for its impactful contribution to the field, currently holding a Q3 ranking in Cancer Research and a Q2 ranking in Oncology, reflecting its importance in disseminating significant advancements and discussions in the field. It is ranked #164 out of 404 in Medicine _ Oncology and #131 out of 230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research on Scopus, indicating its relevance and reach among academic circles. Although it does not offer open access, the journal remains a crucial platform for researchers and professionals seeking to explore contemporary issues in cancer treatment and management. With its commitment to quality and innovation, CURRENT PROBLEMS IN CANCER serves as an essential conduit for knowledge sharing and research development in oncology and cancer science.

CANCER

Exploring the depths of cancer science for better outcomes.
Publisher: WILEYISSN: 0008-543XFrequency: 24 issues/year

CANCER, published by Wiley, stands as a pivotal journal in the field of oncology and cancer research, boasting an impressive impact factor and consistently dynamic growth since its inception in 1948. With an ISSN of 0008-543X and an E-ISSN of 1097-0142, this esteemed journal is recognized for its rigorous peer-reviewed articles, making significant contributions to the understanding of cancer biology, treatment modalities, and clinical practices. CANCER holds a distinguished position in the academic community, securing its placement in the Q1 category for both cancer research and oncology, and ranks within the top percentiles on Scopus, indicating its high impact and relevance. The journal is particularly beneficial for researchers, professionals, and students seeking to stay abreast of the latest advancements in cancer science. By addressing essential research questions and providing pathways for new therapies, CANCER continues to play a crucial role in shaping the future of oncology and improving patient outcomes.

LANCET ONCOLOGY

Leading the way in oncology research and clinical excellence.
Publisher: ELSEVIER SCIENCE INCISSN: 1470-2045Frequency: 12 issues/year

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.

Future Oncology

Empowering oncology through multidisciplinary insights.
Publisher: FUTURE MEDICINE LTDISSN: 1479-6694Frequency: 40 issues/year

Future Oncology is a premier peer-reviewed journal published by FUTURE MEDICINE LTD, dedicated to advancing research and innovation within the field of oncology. Established in 2005 and set to continue through 2024, this journal serves as an essential resource for researchers, healthcare professionals, and students engaged in cancer studies. With its emphasis on groundbreaking findings and multidisciplinary approaches, Future Oncology holds an esteemed reputation, reflected in its 2023 category quartiles ranking it in Q2 for Cancer Research and Q1 for Medicine (miscellaneous). The journal is indexed in Scopus, showcasing its rigorous content, with rankings in the 63rd percentile for Oncology and the 46th percentile for Cancer Research. Although it does not operate on an open-access model, its commitment to disseminating cutting-edge findings makes it an invaluable asset for those seeking to stay at the forefront of oncology research.Future Oncology strives to bridge the gap between laboratory and clinical research, fostering collaboration and appreciation for the complexities of cancer treatment.

Targeted Oncology

Empowering researchers to redefine cancer treatment.
Publisher: SPRINGERISSN: 1776-2596Frequency: 6 issues/year

Targeted Oncology is a premier, peer-reviewed journal published by SPRINGER, focusing on the latest advancements in the field of oncology, specifically targeting the development and application of targeted therapies. Since its inception in 2006, this journal has become an essential resource for researchers, healthcare professionals, and students, providing critical insights into innovative cancer treatments and the pharmacological landscape. Recognized for its impactful contributions, Targeted Oncology holds a distinguished Q1 ranking in both Oncology and Pharmacology categories as of 2023, underscoring its influence and relevance in the scientific community. With an impressive Scopus ranking reflecting its strong citation impact, the journal not only disseminates high-quality research but also facilitates knowledge exchange among oncologists and researchers working towards improving patient outcomes. Although not an Open Access journal, Targeted Oncology is committed to advancing cancer research and therapeutic strategies, making it an invaluable addition to the libraries of any institution dedicated to health and wellness.